Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
BMRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$52.93 - $94.85
Previous CloseN/A
Volume465.01K
Average Volume (3M)1.96M
Market Cap
$11.39B
Enterprise Value$10.83B
Total Cash (Recent Filing)$1.27B
Total Debt (Recent Filing)$595.65M
Price to Earnings (P/E)22.2
Beta0.43
Next Earnings
Aug 05, 2025EPS Estimate
0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.95
Shares Outstanding191,775,670
10 Day Avg. Volume1,934,207
30 Day Avg. Volume1,959,085
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio18.20
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit4.68
Enterprise Value/Ebitda4.67
Forecast
1Y Price Target
$97.88Price Target Upside63.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionBioMarin announced the acquisition of Inozyme, which adds to the company's enzyme replacement therapy (ERT) portfolio with a focus on a rare genetic condition.
Revenue Growth PotentialBioMarin's management reiterated the company's financial guidance and goal of achieving a 40% non-GAAP operating margin in 2026, indicating confidence in future performance.
Strategic AcquisitionThe acquisition of Inozyme is seen as an economical way for BioMarin to increase optionality for future ERT sales.
Bears Say
Market OverhangNavepegritide’s potential impact on Voxzogo's commercial share is considered a near-term stock overhang.
Time To Revenue RealizationThere is sizable revenue potential, but it may take some time to fully materialize.
---
Ownership Overview
0.97% Insiders
35.19% Mutual Funds
40.01% Other Institutional Investors
2.81% Public Companies and Individual Investors
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $52.93 and its highest was $94.85 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $11.39B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Aug 05, 2025 which is in 75 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on May 01, 2025. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.682 by $0.268.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 0.84.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 191,775,670 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0.95 in its last earnings report, beating expectations of $0.682. Following the earnings report the stock price went down -1.084%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Currently, no hedge funds are holding shares in BMRN
---
BioMarin Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.88 (63.32% Upside)
$97.88 (63.32% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 415.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $501.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.21%
12-Months-Change
Fundamentals
Return on Equity
9.64%
Trailing 12-Months
Asset Growth
3.99%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
---
BMRN Company Deck
---
BMRN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
BioMarin reported strong financial performance with notable revenue growth and profitability expansion, supported by successful pipeline progress. However, potential challenges include analyzing exposure to future pharmaceutical tariffs and managing VOXZOGO's revenue dynamics amid global order patterns. The overall sentiment leans towards optimism with strategic growth initiatives and robust financial results.Read More>---
BMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BMRN Stock 12 Month Forecast
Average Price Target
$97.88
▲(63.32% Upside)
Technical Analysis
---